View Clinical Trial (Medical Research Study)

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics - NCT00960765-14221(Clinical Trial 306179)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Williamsville
State:  
NY
Zip Code: 14221
Conditions: Obesity, Morbid - Diabetes Mellitus, Type 2 - Gastric Bypass
Purpose: This research project is designed to investigate endotoxin (a toxin present in the wall of certain kinds of bacteria) levels and the type of bacteria present in the intestine before and after Roux-en-Y gastric bypass or gastric banding surgery in patients that meet the classification for morbid obesity (body mass index >40 kg/m2) and type 2 diabetes. It is known that the type of bacteria present in the intestines of normal weight and obese individuals are different, and it is also known that people with obesity and type 2 diabetes have higher levels of endotoxin. It has been shown that the bacteria change over the long run after Roux-en-Y gastric bypass surgery, but the short-term effects are not known and the endotoxin levels after this procedure have never been studied.
Study summary: Evidence exists that (i) morbidly obese, T2D patients undergoing RYGB are highly likely to resolve T2D symptoms or dramatically reduce oral and/or insulin requirements, (ii) metabolic endotoxemia may incite the pathologic conditions of low-grade inflammation and subsequently insulin resistance, obesity and T2D, (iii) significant intestinal microbiologic flora differences exist between normal weight and obese/diabetic individuals, and (iv) RYGB alters long-term intestinal microbiologic flora. Therefore, it is logical to evaluate short- and long-term circulating endotoxin concentrations and intestinal microbiologic flora in context with weight loss and restoration of euglycemia to expand our knowledge of the mechanism of the benefits observed following RYGB.
Criteria: Inclusion Criteria: - Age > 18 years of age - Morbid obesity (BMI > 40 kg/m2) - Confirmed T2D diagnosis/date of onset Exclusion Criteria: - Age < 18 years of age - BMI < 40 kg/m2 - Type 1 diabetes - Chronic use of non-steroidal anti-inflammatory agents (NSAIDs) - Chronic use of systemic corticosteroids - Anticipated inability to maintain current statin, angiotensin converting enzyme inhibitor (ACEI), or angiotensin receptor blocking agent (ARB) regimen
Study is available at: Synergy Bariatrics
Williamsville, NY 14221
United States

Primary Contact:
Joseph Caruana, MD
Email: jcaruanamd@synergybariatrics.com
Phone: 716-565-3990
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.